Preparing for the incoming wave of biosimilars in oncology

about

Preparing for the incoming wave of biosimilars in oncology

Item

http://www.wikidata.org/entity/Q58762727

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Preparing for the incoming wave of biosimilars in oncology

@en

Preparing for the incoming wave of biosimilars in oncology

@nl

type

Item

label

Preparing for the incoming wave of biosimilars in oncology

@en

Preparing for the incoming wave of biosimilars in oncology

@nl

prefLabel

Preparing for the incoming wave of biosimilars in oncology

@en

Preparing for the incoming wave of biosimilars in oncology

@nl

P1476

Preparing for the incoming wave of biosimilars in oncology

@en

P2093

Elena Wolff-Holz

http://www.w3.org/2001/XMLSchema#string

Elisabeth G E de Vries

http://www.w3.org/2001/XMLSchema#string

Gustaf Befrits

http://www.w3.org/2001/XMLSchema#string

Johan de Munter

http://www.w3.org/2001/XMLSchema#string

Juan Garcia Burgos

http://www.w3.org/2001/XMLSchema#string

Luisa Avedano

http://www.w3.org/2001/XMLSchema#string

Malvika Vyas

http://www.w3.org/2001/XMLSchema#string

Murray Aitken

http://www.w3.org/2001/XMLSchema#string

Rosa Giuliani

http://www.w3.org/2001/XMLSchema#string

Rosa Gonzalez-Quevedo

http://www.w3.org/2001/XMLSchema#string

P2507

Correction: Preparing for the incoming wave of biosimilars in oncology

P2860

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician.

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study

Drift, evolution, and divergence in biologics and biosimilars manufacturing.

Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Interchangeability of Biosimilars: A European Perspective.

Changes in Biosimilar Knowledge among European Crohn's Colitis Organization [ECCO] Members: An Updated Survey.

Authorized manufacturing changes for therapeutic monoclonal antibodies (mAbs) in European Public Assessment Report (EPAR) documents.

Cisplatin otoprotection using transtympanic L-N-acetylcysteine: a pilot randomized study in head and neck cancer patients.

P304

e000420

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ESMOOPEN-2018-000420

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Josep Tabernero

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30245864

http://www.w3.org/2001/XMLSchema#string

P932

6144900

http://www.w3.org/2001/XMLSchema#string